Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on LinkedIn:
“Major Breakthrough: ENHERTU Brings New Hope for Gastric Cancer!
The Independent Data Monitoring Committee has recommended unblinding the DESTINY-Gastric04 trial due to the superior efficacy of ENHERTU!
- For the first time, a HER2-targeted therapy has shown a survival benefit in second-line metastatic gastric cancer.
- ENHERTU significantly prolonged overall survival compared to chemotherapy.
- The results will be shared with global regulatory authorities for full approval.
Gastric cancer has a poor prognosis, with a 5-year survival rate of only 5-10% in advanced stages. This breakthrough could change the treatment landscape for HER2+ gastric cancer!
Expect to hear a lot more about this in upcoming medical conferences—it’s likely to be one of the hottest topics!”
More posts featuring Elvina Almuradova.